On 20th December 2021, the U.S. Food and Drug Administration (FDA) announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months. This will provide an alternative to daily pills for HIV prevention, such as Truvada and […]
